Related Experiment Video
Updated: Jun 13, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block
Luigi Alfano1, Teresa Guida, Livia Provitera
1Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universitá Federico II, 80131 Naples, Italy.
Context:
Mutations of the RET receptor tyrosine kinase are associated to multiple endocrine neoplasia type 2 (MEN2) and sporadic medullary thyroid carcinoma (MTC). The heat shock protein (HSP) 90 chaperone is required for folding and stability of several kinases. HSP90 is specifically inhibited by 17-allyl-amino-17-demethoxygeldanamycin (17-AAG).
Objective:
Our aim was to investigate whether RET protein half-life depends on HSP90 and to dissect the molecular pathway responsible for the degradation of RET upon HSP90 inhibition by 17-AAG.
Design:
17-AAG effects were studied in RAT1 fibroblasts exogenously expressing MEN2-associated RET mutants and human MTC-derived cell lines.
Results:
17-AAG induced a 26S proteasome-dependent degradation of wild-type RET and MEN2-associated RET mutants. The compound hampered HSP90/RET interaction and stabilized RET binding to HSP70, leading to the recruitment of the HSP70-associated E3 ligase C-terminus of Hsc70-interacting protein. In turn, C-terminus of Hsc70-interacting protein polyubiquitinated RET, promoting its proteasomal degradation. 17-AAG blocked RET downstream effectors and RET-dependent transcriptional activation of gene promoters. In human MTC cells carrying oncogenic RET mutants, HSP90 inhibition induced receptor degradation and signaling hindrance leading to cell cycle arrest.
Conclusion:
RET and MEN2-associated RET mutants rely on HSP90 for protein stability, and HSP90 blockade by 17-AAG promotes RET degradation.
Insights
Heat shock protein 90 (HSP90) inhibition by 17-AAG causes RET degradation via the proteasome. This finding is crucial for understanding RET-dependent cancers like medullary thyroid carcinoma (MTC).
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Mutations in the RET receptor tyrosine kinase are linked to multiple endocrine neoplasia type 2 (MEN2) and sporadic medullary thyroid carcinoma (MTC).
- Heat shock protein (HSP) 90 is essential for the stability and proper folding of various kinases, including RET.
- 17-allyl-amino-17-demethoxygeldanamycin (17-AAG) is a specific inhibitor of HSP90.
Purpose of the Study:
- To determine if RET protein stability is dependent on HSP90.
- To elucidate the molecular mechanisms by which HSP90 inhibition leads to RET degradation.
Main Methods:
- Investigated the effects of 17-AAG in RAT1 fibroblasts expressing MEN2-associated RET mutants.
- Utilized human MTC-derived cell lines for experimental analysis.
- Assessed protein degradation pathways, including the 26S proteasome and E3 ligase interactions.
Main Results:
- 17-AAG induced 26S proteasome-dependent degradation of both wild-type RET and MEN2 RET mutants.
- HSP90 inhibition disrupted the HSP90/RET interaction, stabilized RET binding to HSP70, and promoted RET ubiquitination and proteasomal degradation.
- 17-AAG effectively blocked RET downstream signaling and RET-dependent transcriptional activation, leading to cell cycle arrest in MTC cells.
Conclusions:
- RET and its MEN2-associated mutants require HSP90 for their stability.
- HSP90 blockade by 17-AAG triggers the degradation of RET, offering a potential therapeutic strategy.
Related Concept Videos
Export of Misfolded Proteins out of the ER
Molecular Chaperones and Protein Folding
The...
Regulation of the Unfolded Protein Response
The Unfolded Protein Response
Bacterial Protein Maturation
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...

